Nov 12, 2025 07:02AM Esperion Therapeutics' (ESPR) Portfolio Not Fully Priced In - Cantor Fitzgerald

Nov 12, 2025 04:57AM Esperion Therapeutics' (ESPR) LDL-Lowering Drug Supported by KOLs - Citizens

Nov 6, 2025 06:31AM Esperion Therapeutics (ESPR) Misses Q3 EPS by 18c

Oct 17, 2025 07:12AM Cantor Fitzgerald Reiterates Overweight Rating on Esperion Therapeutics (ESPR): Says Expenses Manageable

Oct 17, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)

Oct 6, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)

Oct 3, 2025 08:00AM Esperion settles patent dispute with Dr. Reddy's over generic drugs

Sep 22, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)

Sep 22, 2025 04:24AM Citizens JMP Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)

Sep 19, 2025 08:02AM Otsuka receives approval to market NEXLETOL in Japan for cholesterol

Aug 11, 2025 04:13PM Esperion delays Q2 quarterly report filing due to financial close issues

Aug 5, 2025 06:19AM Esperion Therapeutics (ESPR) Tops Q2 EPS by 12c

Jul 24, 2025 12:48PM Esperion Therapeutics (ESPR) on watch on vague chatter

Jul 8, 2025 08:01AM Esperion (ESPR) settles with Accord Healthcare over NEXLETOL generic

Jul 1, 2025 08:07AM Esperion Therapeutics (ESPR) Appoints Craig Thompson to its Board

Jun 17, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)

Jun 13, 2025 07:18AM Cantor Fitzgerald Reiterates Overweight Rating on Esperion Therapeutics (ESPR)

Jun 2, 2025 08:03AM Esperion Therapeutics (ESPR) Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL

May 12, 2025 08:03AM Esperion Therapeutics (ESPR) Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL Prior to April 19, 2040

May 8, 2025 06:30AM Esperion Therapeutics (ESPR) Partners with HLS Therapeutics to Commercialize NEXLETOL and NEXLIZET in Canada

May 6, 2025 06:37AM Esperion Therapeutics (ESPR) Misses Q1 EPS by 5c

Apr 25, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)

Apr 24, 2025 08:03AM Esperion Therapeutics (ESPR) Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 1, 2025 08:03AM Esperion Therapeutics (ESPR) Appoints Robert E. Hoffman to its Board

Mar 24, 2025 05:45AM Citizens JMP Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)

Mar 20, 2025 08:00AM Esperion Therapeutics (ESPR) Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid

Mar 5, 2025 05:28AM Citizens JMP Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)

Mar 4, 2025 06:09AM Esperion Therapeutics (ESPR) Tops Q4 EPS by 3c

Mar 3, 2025 08:01AM Esperion Therapeutics (ESPR) Partners with CSL Seqirus to Commercialize NEXLETOL and NEXLIZET in Australia

Feb 11, 2025 06:45AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)

Feb 11, 2025 04:13AM JMP securities lowers Esperion Therapeutics Price Target to $4 (ESPR)

Jan 23, 2025 07:07AM JMP Securities Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)

Jan 16, 2025 10:28AM Esperion Therapeutics (ESPR): research & development expenses are expected to be in the range of $55 million to $65 million

Dec 18, 2024 07:01AM Esperion Therapeutics (ESPR) Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 18, 2024 04:26AM Goldman Sachs Reinstates Esperion Therapeutics (ESPR) at Neutral

Dec 17, 2024 06:32AM Cantor Fitzgerald Starts Esperion Therapeutics (ESPR) at Overweight

Dec 13, 2024 06:15AM Esperion Therapeutics (ESPR) Announces $210M Convertible Debt Financing

Dec 12, 2024 08:01AM Esperion Therapeutics (ESPR) Partners with Neopharm to Commercialize NEXLETOL and NEXLIZET in Israel

Dec 3, 2024 07:02AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)

Dec 2, 2024 08:01AM Esperion Therapeutics (ESPR) Announces New Drug Submissions in Canada for NEXLETOL and NEXLIZET Treatments to Reduce LDL-C and Cardiovascular Risk

Nov 26, 2024 08:00AM Esperion Therapeutics (ESPR): Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia

Oct 3, 2024 06:58AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)

Oct 2, 2024 08:01AM Esperion Therapeutics (ESPR) EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid

Sep 3, 2024 08:10AM Esperion (ESPR) Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL and NEXLIZET

Aug 12, 2024 06:06AM Esperion Therapeutics (ESPR) Misses Q2 EPS by 17c, provides guidance

Jul 1, 2024 06:41AM H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)

Jun 28, 2024 07:02AM Esperion Therapeutics (ESPR) Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility

Jun 20, 2024 08:12AM BofA Securities Downgrades Esperion Therapeutics (ESPR) to Underperform